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Introduction

Results

Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most
common cancer type and has an annual incidence of over 40,000
new cases in the US, and over 500,000 worldwide (1). The cure rate
for patients with advanced HNSCC remains in the 25-40% range due
to resistance to standard therapy, primarily consisting of platinumbased chemoradiation therapy (2). Mutation of the TP53 is the most
common aberration in head and neck cancer and often associated
poor survival and treatment resistance (3). Therefore, novel
therapeutic approaches to overcome this resistance are urgently
needed. As WT p53 protein is a known potent inducer of apoptosis
and senescence when expressed in tumor cells, reactivation of some
level of WT function in mutant TP53 bearing cells is an attractive
therapeutic strategy. APR-246, a methylated PRIMA-1 analog, is a
novel, first-in-class, small molecule that selectively induces apoptosis
in TP53 mutant cancer cells. Mechanistically, APR-246 is
spontaneously converted into the active form methylene
quinuclidinone (MQ), and covalently capable of binding to cysteine
residues in mutant p53 thereby producing a thermodynamically stable
protein and shifting equilibrium toward a functional conformation (4-6).

Purpose
The goal of this study was to test the effect of APR-246 on various
HNSCC cell lines with different TP53 mutational status as a single
agent and in combination with cisplatin-based therapy and to
examine the mechanism of action of APR-246 in these cell lines.

Methods
Clonogenic survival assays were used to examine in vitro
sensitivity of HNSCC cell lines harboring a variety of TP53
mutations to APR-246. Western blotting was performed to
dissect molecular mechanisms. Briefly, HNSCC cells were
seeded at predetermined densities and treated with various
doses of APR-246 and/or cisplatin for clonogenic survival
assays. For western blotting, cells were treated with a dose of
the drug that is determined based on the IC50 of APR-246 and
harvested at different time points. Controls were treated with
DMSO. The Talalay-Chow Combination Index and Isobologram
method was used to evaluate the drug synergistic interactions in
the cells tested. Immunostaining with Pab240 (recognizes
mutant p53) and Pab1640 (recognizes wildtype p53) antibodies
were used to test for the proper conformational changes and
reactivation of p53 in the mutant p53 HNSCC cells.
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Figure 2. APR-246 induces conformational
changes in HNSCC mutant TP53 cell lines.
Isogenic HNSCC cell lines with wildtype p53
and different p53 mutation were treated with
APR-246 for 24 hours and stained with the
PAb240 antibody (recognizes mutant p53
protein) as indicated. A) Image representative
of immunostaining of the PAb240 in the wild
type p53 cells (negative control). B-C)
PAb240 immunostaining was decreased in the
mutant cell lines following treatment with the
APR-246, indicating changes from mutant to
wild type p53 structure. These results suggest
reactivation of wildtype p53 in the mutant p53
cell lines tested.

A)
Figure 1. APR-246 induces p21 in HNSCC mutant p53 cell lines. The cell lines
were treated with APR-246 dose at different time points as indicated. Protein lysates
were collected and subjected to western blot analysis with appropriate antibodies. No
induction of p21 was observed in the wtp53 (A). APR-246 treatment resulted in
significant p21 (primary downstream target of p53) induction within 6 hours following
treatment with the drug in the mutant p53 cell lines (B-D), indicating reactivation of
p53. Addition of the APR-246 as single agent caused apoptotic cell death as
determined by PARP-1 cleavage (E).
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Figure 3. Clonogenic survival assay showing single agent activity based on IC50
for cisplatin (CDDP) and APR-246 in HNSCC cells. HNSCC cell line (HN31) was
treated with APR-246 (0-50 µmol/L) alone, in combination with cisplatin (0-5 µmol/L )
and subjected to clonogenic survival analysis. Representative images of clonogenic
survival are shown in A. We used the human HN31 p53 mutant cell line to explore the
degree of sensitivity to cisplatin and APR-246 in vitro. We calculated dose-response
curves and the cell line tested was resistant to cisplatin in agreement with the
published IC50 (B). The cells seemed to display some degree of sensitivity to APR-246
with an IC50 value of 2.43 µmol/L (C), compared to other tumor types.
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Conclusions
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Figure 3 (cont). APR-246 synergizes with cisplatin in vitro in HNSCC cells
expressing mutant p53. Results showed that APR-246 decreased cell survival of
these mutant HNSCC cells and synergized with cisplatin in vitro. The combination
index therapy determined by Talalay-Chow method is shown in D. CI <1.0 indicates
synergism, CI = 1, indicates additivity, and CI > 1.0 indicates antagonism. Addition of
APR-246 to cisplatin resulted in CI = 0.76 at the effective dose (ED50) that killed 50%
of the cells following treatment with the two drugs. Drugs were used at constant ratio of
1:10 as indicated.

•

APR-246 reactivates the HNSCC expressing p53 mutations
in vitro through induction of conformational changes.

•

APR-246 displays single agent activity and sensitizes the
HNSCC harboring p53 mutation to cisplatin.

•

APR-246 enhances cell killing through induction of
apoptosis in HNSCC.

